Latest news

Atisama Therapeutics Appoints Young Kwon PhD as Non-Executive Director

Dr Kwon joins the Board to help shape Atisama’s strategy and capital pathway as the Company advances its splice-switching oligonucleotide (SSO) platform. Atisama’s lead asset, RB042, an inhaled SSO therapy for COPD, in Phase 1, with a growing pipeline of SSO programmes across lung, liver, kidney, ocular and CNS indications. Dr Kwon brings more than 25 years as an investor and senior executive in private and public biotech companies, including as CEO of Alchemab Therapeutics a

Oct 143 min read

Atisama Therapeutics and Monash University awarded non-dilutive $15M MRFF Grant to fund Phase 1a/1b Clinical Trial for lead asset RB042

Funding will support early clinical development of RB042, an inhaled SSO therapy for chronic obstructive pulmonary disease and potentially other chronic inflammatory conditions. MELBOURNE, AUSTRALIA, 30 June 2026 — Atisama Therapeutics (“Atisama” or the “Company”), an Australian clinical-stage biotechnology company developing precision splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, welcomed the recent announcement that the Australian G

Jul 22 min read

Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board

RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date. Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors. MELBOURNE, AUSTRALIA, 15 May 2026 — Atisama Therapeutics (formerly Rage Bio) (“Atisama” or the “Company”), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide

May 153 min read

Rage Bio Becomes Atisama Therapeutics

Rebrand marks transition into clinical-stage development and expansion of preclinical programs into new inflammatory disease targets using SSO platform. MELBOURNE, AUSTRALIA, 15 May 2026 — Atisama Therapeutics (formerly Rage Bio) (“Atisama” or the “Company”), an Australian clinical-stage biotechnology company developing precision splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today announced its rebrand from Rage Bio to Atisama Therapeut

May 142 min read

Rage Bio secures AU$29 million in Series A funding. Appoints Siro Perez as Chief Executive Officer & Edwin Tucker as Chief Medical and Development Officer.

Melbourne, Australia – RAGE Biotech Pty Ltd (‘Rage Bio’), a company developing precision splice-switching oligonucleotide (SSO) therapeutics to fight chronic inflammatory disease, has raised $A29 million in its Series A funding round. Rage Bio has also announced two key executive appointments, naming Dr Siro Perez as Chief Executive Officer and Dr. Edwin Tucker as Chief Medical and Development Officer. The funding round was led by IP Group Australia and Hostplus, with continu

May 114 min read